b5media.com

Advertise with us

Enjoying this blog? Check out the rest of the Health & Wellness Channel Subscribe to this Feed

Genetics and Health

Genelex Supports Pharmacogenetic Testing

by Hsien Hsien Lei, PhD on December 8th, 2006

Genelex CEO and founder Howard Coleman is making a strong push for patients to be tested for specific genes involved in the processing of drugs. In response to a recent FDA advisory panel recommendation to allow Pfizer to market Celebrex (celecoxib) for use in the treatment of juvenile rheumatoid arthritis, he said:

…thousands of children have an inability to process Celebrex safely. A simple DNA test that tests for the CYP2C9 enzyme alerts parents and physicians that the drug could cause harm to the child.”

No medicine that could potentially harm patients should ever be prescribed without knowing how that individual processes the drug. It is time patients and parents responsibly determine how a drug will affect them before it is ever swallowed.

An estimated 5 percent of the total population has difficulties metabolizing Celebrex which could result in overdose. Celebrex has already been approved to treat osteoarthritis and adult rheumatoid arthritis without any requirement for prior DNA testing. But companies like Genelex and and DNA Direct hope to change that by offering direct-to-consumer pharmacogenetic testing.

Medical News Today, December 8, 2006

Technorati Tags: , , , , , , , , , , , ,

POSTED IN: Genetic Testing

2 opinions for Genelex Supports Pharmacogenetic Testing

Have an opinion? Leave a comment: